| Identification | Back Directory | [Name]
1(2H)-Phthalazinone, 4-[[3-[[3-[(cyclopropylamino)methyl]-1-azetidinyl]carbonyl]-4-fluorophenyl]methyl]-, hydrochloride (1:1) | [CAS]
1681020-60-9 | [Synonyms]
IDX-1197 hydrochloride
Venadaparib hydrochloride
1(2H)-Phthalazinone, 4-[[3-[[3-[(cyclopropylamino)methyl]-1-azetidinyl]carbonyl]-4-fluorophenyl]methyl]-, hydrochloride (1:1) | [Molecular Formula]
C23H24ClFN4O2 | [MOL File]
1681020-60-9.mol | [Molecular Weight]
442.92 |
| Hazard Information | Back Directory | [Uses]
Venadaparib (IDX-1197) hydrochloride is a potent and selective PARP inhibitor with anticancer activities. Venadaparib hydrochloride can be used for solid tumors research[1][2]. | [in vivo]
In the germline BRCA1-mutated ovarian cancer PDX model, oral administration of Venadaparib (IDX-1197) exhibits significant PAR inhibition (>90%) in tumor tissues until 24 hr post dose. Venadaparib also dose-dependently led to potent tumor growth inhibition compared to Olaparib treatment group[1]. | [IC 50]
PARP1: 1.4 nM (IC50); PARP2: 1 nM (IC50) | [References]
[1] Yong Man Kim, et al. First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 39, no. 15_suppl (May 20, 2021) 3107-3107.
[2] Jae-Hoon Kang, et al. A novel phtalazinone derivatives and manufacturing process thereof. WO2015037939A1. |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|